Cryo-Cell International (STU:ZCY) EPS (Basic): €-0.29 (TTM As of Feb. 2026)

What is Cryo-Cell International EPS (Basic)?

Cryo-Cell International STU:ZCY -2.52% 58 EPS (Basic) is €-0.29 as of Feb. 2026. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €6.10 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cryo-Cell International's basic earnings per share (Basic EPS) for the three months ended in Feb. 2026 was €0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Feb. 2026 was €-0.29.

Cryo-Cell International's EPS (Diluted) for the three months ended in Feb. 2026 was €0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 was €-0.29.

Cryo-Cell International's EPS without NRI for the three months ended in Feb. 2026 was €0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2026 was 0.17.

During the past 3 years, the average EPS without NRI Growth Rate was -11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Cryo-Cell International's highest 3-Year average EPS without NRI Growth Rate was 79.40% per year. The lowest was -55.80% per year. And the median was -1.80% per year.

Cryo-Cell International (STU:ZCY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cryo-Cell International EPS (Basic) Related Terms

Cryo-Cell International EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International EPS (Basic) Chart

Cryo-Cell International Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Nov24

Nov25

EPS (Basic)

Get a 7-Day Free Trial

0.21

0.32

-1.06

0.05

-0.26

Cryo-Cell International Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
EPS (Basic)	Get a 7-Day Free Trial															0.03	0.04	0.08	-0.41	0.01

58GF Score

Cryo-Cell International Inc STU:ZCY

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cryo-Cell International EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cryo-Cell International's Basic EPS for the fiscal year that ended in Nov. 2025 is calculated as

Basic EPS (A: Nov. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.101	-	0)	/	8.069
	=	-0.26

Cryo-Cell International's Basic EPS for the quarter that ended in Feb. 2026 is calculated as

Basic EPS (Q: Feb. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0.04	-	0)	/	8.055
	=	0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.29

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of €-0.29 mean?

Cryo-Cell International (STU:ZCY) has a EPS (Basic) of €-0.29 as of Feb. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cryo-Cell International and its competitors.

Is Cryo-Cell International's EPS (Basic) too high?

Cryo-Cell International's current EPS (Basic) is €-0.29. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Cryo-Cell International's EPS (Basic) compare to CDIX and EHSI?

Cryo-Cell International's EPS (Basic) of €-0.29 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Healthcare Providers & Services company?

A good EPS (Basic) depends on the Healthcare Providers & Services industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current EPS (Basic) is €-0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cryo-Cell International stock overvalued right now?

Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €6.10, compared to a current price of €3.10 — trading 49.2% below its estimated fair value. The current EPS (Basic) is €-0.29. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current EPS (Basic) is €-0.29 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €3.10 is trading 49.2% below its estimated GF Value™ of €6.10. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for STU:ZCY:

EPS (Basic): €-0.29
GF Value™: €6.10 vs. price of €3.10 (49.2% below fair value)
GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies CDIX EHSI CCM PIII BMGL BICX AMS GBCS NUMIF HLYK HCA XTER:FRE SAU:4013 XKLS:5225 THC BSP:RDOR3 SZSE:300015 DVA NSE:APOLLOHOSP XTER:FME

Other Exchanges CCEL:USA ZCY:Germany

Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677

Website https://www.cryo-cell.com

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

58GF Score

Get the complete analysis for STU:ZCY

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10

Price

€6.10

GF Value

View STU:ZCY Analysis

See EPS (Basic) data for all stocks →